Evidence map›Paper›PMID 39246468›Full record

ArticleACS omega2024

Shape-Specific Gold Nanoparticles for Multiplex Biosensing Applications.

Shixi Zhang, Yuhan Zhang, Jiaye Jiang, Mathias Charconnet, Yuan Peng, Lei Zhang, Charles H Lawrie

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shixi ZhangSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Yuhan ZhangSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Jiaye JiangSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Mathias CharconnetSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Yuan PengSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Lei ZhangSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.
Charles H LawrieSino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai 201899, China.ORCID https://orcid.org/0000-0002-8882-1131

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The biosensing field faces a significant challenge in efficiently detecting multiple analytes in a single diagnostic sample in order to compete with other established multiplex molecular diagnostic technologies such as PCR and ELISA. In response, we have developed a colorimetric nanobiosensor based on multiple morphological forms of functionalized gold nanoparticles (AuNPs) for the simultaneous detection of the influenza virus and SARS-CoV-2 virus. Gold nanospheres (GNSp) were modified with oligonucleotides specific for the influenza A virus, while gold nanoshells (GNSh) were modified with oligonucleotides specific for the SARS-CoV-2 virus. In the presence of their respective targets, AuNPs remain stable due to DNA-DNA interactions; conversely, in the absence of targets, AuNPs aggregate. Consequently, the hybrid system exhibits an indigo color with the SARS-CoV-2 target, a blue color with the Influenza A target, and a purple color with both targets, visible to the naked eye. Analytical sensitivity was 100 nM, and no cross-reactivity was observed with potentially confounding pathogens. This approach holds great promise for the simultaneous identification of multiple pathogens in a rapid manner without the need for equipment or trained personnel.

Identifiers

PMID39246468
PMCPMC11375896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.